Debbie Rigby takes a look at the latest in research news
Evaluation Of patients in the ORBIT-AF II trial shows 541 NOAC-treated patients (9.4%) were underdosed, 197 were overdosed (3.4%), and 5,000 were dosed according to U.S. labeling (87%). NOAC overdosing was associated with increased all-cause mortality compared with recommended doses; whereas, underdosing was associated with increased cardiovascular hospitalization.
Journal of the American College of Cardiology 2016;68:2597–604.
An Australian study of a large population-based sample (n= 4229 children) has shown gestational vitamin D deficiency is associated with autism-related traits. This finding suggests that infants exposed to persistent low vitamin D from mid-gestation until birth may be at risk for autism-related traits. The authors speculate that prenatal vitamin D supplementation may reduce the incidence of ASD.
Molecular Psychiatry 2016;00:1–7.
This updated guidance on the treatment of exercise-induced bronchoconstriction highlights intermittent use of inhaled short-acting β2-adrenergic receptor agonists for protection against EIB; and daily therapy with leukotriene inhibitors. Daily ICS/LABAs should be restricted to patients with moderate-to-severe persistent asthma. Regular use of SABAs and LABAs can cause tolerance, limiting their ability to provide bronchoprotection and bronchodilation.
Allergy Clin Immunol 2016;138:1292-5.
In this large, population based study the use of incretin based drugs (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists) was not associated with an increased risk of pancreatic cancer compared with sulfonylureas.